Senate Files

Bills

S. 3345 119th Congress

PBM Price Transparency and Accountability Act

Latest action, Dec 4, 2025: Read twice and referred to the Committee on Finance.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

27 cosponsors

Sponsored by Mike Crapo (Republican). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
12 D · 15 R
  • Democrat
  • Republican
  • Independent
27 senators cosponsoring

Referred to: Senate: Finance Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

22 clientsQ4 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

AMGEN INC
4 reports
CAMBIA HEALTH SOLUTIONS
4 reports
CVS HEALTH (AND SUBSIDIARIES)
4 reports
EMD SERONO INC
4 reports
FOOD MARKETPLACE INC
4 reports
GSK (FKA GLAXOSMITHKLINE INC.)
4 reports
INDEPENDENT PHARMACY COOPERATIVE
4 reports
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
4 reports
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
4 reports
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
E3 STRATEGIC CONSULTING GROUP
4 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
4 reports
NATIONAL ASSOCIATION OF CHAIN DRUG STORES
3 reports
SOUTHEAST GEORGIA HOSPITAL SYSTEM
CAROL G HOLLADAY & ASSOCIATES
3 reports
AMERICAN BENEFITS COUNCIL
2 reports
BIOGEN
2 reports
All 25 of 26 clients
ClientLobbying firmReportsReports totalingFromToSenate
AMGEN INC4$11.7MQ4 2025Q3 2026yes
CAMBIA HEALTH SOLUTIONS4$2.6MQ4 2025Q3 2026yes
CVS HEALTH (AND SUBSIDIARIES)4$11.2MQ4 2025Q3 2026yes
EMD SERONO INC4$2.9MQ4 2025Q3 2026yes
FOOD MARKETPLACE INC4$2.2MQ4 2025Q3 2026yes
GSK (FKA GLAXOSMITHKLINE INC.)4$4.9MQ4 2025Q3 2026yes
INDEPENDENT PHARMACY COOPERATIVE4$170KQ4 2025Q3 2026yes
NATIONAL COMMUNITY PHARMACISTS ASSOCIATION4$1.2MQ4 2025Q3 2026yes
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION4$12.7MQ4 2025Q3 2026yes
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATIONE3 STRATEGIC CONSULTING GROUP4$230KQ4 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA4$35.0MQ4 2025Q3 2026yes
NATIONAL ASSOCIATION OF CHAIN DRUG STORES3$1.1MQ1 2026Q3 2026yes
SOUTHEAST GEORGIA HOSPITAL SYSTEMCAROL G HOLLADAY & ASSOCIATES3$66KQ4 2025Q2 2026yes
AMERICAN BENEFITS COUNCIL2$550KQ2 2026Q3 2026yes
BIOGEN2$2.5MQ1 2026Q2 2026yes
LUNDBECK LLC2$300KQ4 2025Q1 2026yes
OLIN CORPORATION2$490KQ4 2025Q1 2026yes
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)FIERCE GOVERNMENT RELATIONS2$120KQ4 2025Q1 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICATHE MCMANUS GROUP2$0Q4 2025Q1 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)DESIMONE CONSULTING, LLC2$70KQ4 2025Q1 2026yes
AARP1$5.3MQ4 2025Q4 2025yes
CAMBIA HEALTH SOLUTIONS (FORMERLY KNOWN AS THE REGENCE GROUP)RED+BLUE STRATEGIES1$80KQ4 2025Q4 2025yes
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATIONDAVE KOLBE CONSULTING1$30KQ1 2026Q1 2026—
PRIME THERAPEUTICS1$100KQ4 2025Q4 2025yes
PRIME THERAPEUTICSGOVERNMENT COUNSEL, LLC1$0Q4 2025Q4 2025yes